|Bid||35.25 x 900|
|Ask||35.24 x 900|
|Day's Range||34.99 - 35.46|
|52 Week Range||31.43 - 48.25|
|Beta (5Y Monthly)||0.34|
|PE Ratio (TTM)||35.51|
|Forward Dividend & Yield||1.89 (5.35%)|
|Ex-Dividend Date||May 14, 2020|
|1y Target Est||N/A|
Glaxo's (GSK) Pharmaceutical and Consumer Healthcare segments are likely to have driven third-quarter sales. Results will provide clarity on the impact of coronavirus on the company's vaccine business.
As COVID-19 infections rise, people seeking to avoid one lung disease compounding another are queuing up to get inoculated against bacterial pneumonia, causing shortages of a Merck & Co vaccine in parts of Europe. Demand for Merck's Pneumovax 23, which is used to prevent pneumococcal lung infections, has hit record highs across the world, the company said. Pneumococcal prevention, the largest segment of the vaccine market by value, rang up about $7 billion in sales in 2019, contested by Pfizer, Merck and GlaxoSmithKline.
GlaxoSmithKline is testing two vaccines that could protect newborns and people over age 60 from RSV, a virus that has defied vaccine developers for years.